$464 Mln
$207 Mln
--
As on 02-Oct-2023 16:00 EDT
$0.06
•
0.32%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
| 50.36 | 65.19 | 68.17 | 33.33 | -23.83 | -31.84 | -13.22 |
|
S&P BSE Sensex*
| 7.76 | 0.27 | 1.30 | 14.16 | 19.21 | 12.41 | 12.88 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Intercept Pharmaceuticals (ICPT)
| -24.06 | -34.05 | -80.07 | 22.95 | 72.01 | -46.23 | -27.25 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Intercept Pharmaceuticals Inc. (ICPT) stood at $ 995 Mln as on 31-Mar-23
The share price of Intercept Pharmaceuticals Inc. (ICPT) is $18.600000 (NASDAQ) as of 02-Oct-2023 16:00 EDT. Intercept Pharmaceuticals Inc. (ICPT) has given a return of -23.83% in the last 3 years.
Intercept Pharmaceuticals Inc. (ICPT) has a market capitalisation of $ 464 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Intercept Pharmaceuticals Inc. (ICPT) is 44.19 times as on 02-Jun-2023, a 16.4% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Intercept Pharmaceuticals Inc. (ICPT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Intercept Pharmaceuticals Inc. (ICPT) and enter the required number of quantities and click on buy to purchase the shares of Intercept Pharmaceuticals Inc. (ICPT).
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.
The CEO & director of Mr. Jerome B. Durso. is Intercept Pharmaceuticals Inc. (ICPT), and CFO & Sr. VP is Mr. Andrew Saik.
The promoters of Intercept Pharmaceuticals Inc. (ICPT) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
313
|
|
|
286
|
|
|
34
|
|
|
10
|
| Intercept Pharmaceuticals Inc. (ICPT) | Ratios |
|---|---|
|
Return on equity(%)
|
124.75
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
3.32
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Intercept Pharmaceuticals Inc. (ICPT) was $207 Mln.
$463.56 Mln
$294.52 Mln
$206.97 Mln
$433.60 Mln
$333.04 Mln
High
$8.82 - 21.86
41,687,100
NASDAQ: ICPT
New York, NY
https://www.interceptpharma.com
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a... farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
